Kenneth Schor, MD
Ophthalmology · Chevy Chase, MDNPI 1407009228
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,406 of the $11,928 with a category attached, or 78.9%. 23 manufacturers reported payments, led by NEW World Medical,inc. at 29.3% of the total. Reporting peaked in 2023 at $3,409 and has fallen 65.3% since, to $1,184 in 2025.
Across 271 payments — averaging $44.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$3K
- AbbVie$2K
- Alcon$2K
- Sun Pharmaceutical Industries Inc.$631
- Glaukos Corporation$412
- Tarsus Pharmaceuticals, Inc.$389
- plus $3K from 17 others
Across 36 payments — averaging $2040.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$73K
What the payments were for
- Speaking & faculty fees$1,53913%
- Travel & lodging$9488%
- Food & beverage$9,40679%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 11 | $3,499 |
| AbbVie(2 entities) | 87 | $2,099 |
| Alcon | 35 | $2,069 |
| Sun Pharmaceutical Industries Inc. | 25 | $631 |
| Glaukos Corporation | 7 | $412 |
| Tarsus Pharmaceuticals, Inc. | 14 | $389 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $330 |
| Heru, Inc. | 1 | $316 |
| Sight Sciences, Inc. | 9 | $310 |
| Bausch & Lomb Americas Inc. | 10 | $300 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $285 |
| Ivantis, Inc | 2 | $235 |
| Oyster Point Pharma, Inc. | 11 | $234 |
| Novartis | 20 | $226 |
| Shire North American Group Inc | 1 | $123 |
| Aerie Pharmaceuticals, Inc. | 1 | $116 |
| Rxsight Inc | 3 | $99 |
| Kala Pharmaceuticals, Inc. | 4 | $74 |
| Harrow Eye, LLC | 2 | $45 |
| Biotissue Holdings Inc. | 2 | $45 |
| Thea Pharma Inc. | 2 | $44 |
| Eyevance Pharmaceuticals LLC | 1 | $26 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,206
- Ahmed Glaucoma Valve$1,121
- Kahook Dual Blade$1,121
- Heru HMD$316
- Hydrus$184
- XEN GLAUCOMA TREATMENT SYSTEM$150
- Clearpath$135
- Streamline$135
- Tecnis IOL$134
- XIIDRA$123
- XEN$119
- LUMIGAN$117
- Rhopressa$116
- Rocklatan$116
- ARGOS$113
- ENVISTA TORIC$106
- OMNI(R) SURGICAL SYSTEM (US)$106
How this compares
$11,928 in reported general payments places this provider in the 85th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 118 | $65,407 |
| RestasisCyclosporine | 32 | $41,494 |
| CombiganBrimonidine Tartrate/Timolol | 59 | $28,175 |
| RhopressaNetarsudil Mesylate | 49 | $26,511 |
| VyzultaLatanoprostene Bunod | 55 | $23,501 |
| CequaCyclosporine | 16 | $12,757 |
| Brinzolamide | 57 | $12,592 |
| Alphagan PBrimonidine Tartrate | 27 | $12,082 |
| Travoprost | 50 | $10,652 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $10,135 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 45 | $9,360 |
| TafluprostTafluprost/Pf | 26 | $8,228 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 48 | $8,115 |
| Timolol MaleateTimolol Maleate/Pf | 21 | $7,881 |
| Timolol Maleate | 247 | $7,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,099 | $147,157236 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $116 | $36,64668 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $300 | $23,50155 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $631 | $12,75716 claims |
| AlconSimbrinza | $2,069 | $9,36045 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $234 | $7,64811 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $285 | $3,38021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Chevy Chase
- Anand MantravadiChevy Chase$134K
- Deepika ShahChevy Chase$122K
- Thomas ClinchChevy Chase$104K
- Hylton MayerChevy Chase$52K
- Neil MartinChevy Chase$13K
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.